ABP 710 (infliximab)
- Region
- 🇪🇺 EU
- Active substance
- infliximab
- Company
- Amgen Europe B.V.
- Status
- Application withdrawn
- Application
- EMEA/H/C/005020
- ATC
- L04AB02
- Official record
- www.ema.europa.eu
Indication
Treatment of rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, psoriasis and ulcerative colitis
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Flixabi Authorised · Samsung Bioepis NL B.V.
- 🇪🇺 Remicade Authorised · Janssen Cilag International NV
- 🇪🇺 Inflectra Withdrawn · Pfizer Europe MA EEIG
- 🇪🇺 Veblocema Application withdrawn · Celltrion Healthcare Hungary Kft.
- 🇪🇺 Remsima Authorised · Celltrion Healthcare Hungary Kft.
- 🇪🇺 Zessly Authorised · Sandoz GmbH
Follow ABP 710
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.